Used as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6, this compound plays a key role in cancer research. It interferes with the cell cycle progression in tumor cells, especially those with dysregulated retinoblastoma (Rb) protein pathways, leading to cell cycle arrest and inhibition of proliferation. It is widely applied in preclinical studies for evaluating therapies against breast cancer, leukemia, and other malignancies dependent on CDK4/6 activity. Its ability to selectively target cancer cells while sparing normal cells makes it a valuable tool in developing targeted oncology treatments.